Lilly Makes $3.8B Bet on Building Infectious Disease Portfolio

On May 26, 2026, Eli Lilly announced agreements to acquire three biotechnology companies—Curevo, LimmaTech Biologics, and Vaccine Company—in deals valued collectively at up to $3.83 billion.1 The transactions signal a deliberate expansion into infectious disease prevention, with each acquisition targeting a distinct pathogen class and technology platform.

The strategic thread connecting all three deals is the concept of upstream intervention.1 Rather than developing treatments for conditions like dementia or multiple sclerosis directly, Lilly is investing in preventing the infections implicated in their development, which can represent a more efficient path. Shingles vaccination, for instance, has been associated in population studies with reduced dementia risk, and there is growing evidence linking the Epstein-Barr virus to multiple sclerosis and several malignancies. The framing of vaccines being tools for reducing long-term disease burden rather than simply preventing acute infection, has implications for how these treatments will be positioned in development and eventually in regulatory submissions.

The Curevo acquisition, worth up to $1.5 billion, centers on amezosvatein, an adjuvanted subunit vaccine candidate for shingles prevention.1 The current standard of care, while effective, carries tolerability challenges that contribute to second-dose hesitancy. Curevo engineered amezosvatein with a next-generation synthetic adjuvant intended to address this. In a phase 2 head-to-head trial, the candidate matched immune response on primary endpoints while cutting rates of activity-limiting fatigue, chills, and injection-site pain by more than half. From a manufacturing standpoint, synthetic adjuvant technology represents a formulation challenge that differs meaningfully from established aluminum salt or oil-in-water systems, and scaling this platform will require careful process development attention.

What Do These Platforms Demand on the Development and Manufacturing Fronts?

The LimmaTech Biologics acquisition, valued at up to $780 million, introduces a bacterial vaccine platform targeting pathogens for which antimicrobial resistance is progressively limiting treatment options including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis.1 The platform is designed to generate immune responses against the toxins and superantigens these bacteria produce, rather than surface antigens alone. The lead candidate, targeting S. aureus as a cause of surgical-site infection, is currently in phase 1. Complex bacterial vaccine antigens of this type present distinct bioprocess challenges compared to viral platforms, particularly around consistency of antigen folding and conjugation at scale.

The third acquisition, Vaccine Company, which shareholders could receive up to $1.55 billion, brings in a proprietary nanoparticle technology platform designed to replicate the antigen display properties of virus-like particle vaccines without the manufacturing burden those platforms typically impose.1 The lead program applies this approach to Epstein-Barr virus with a five-antigen candidate described as phase 1-ready. If the platform performs as designed, it could represent an advance in the manufacturability of complex particle-based vaccines.

All three transactions remain subject to regulatory clearance.1 Lilly has indicated it will determine the accounting treatment following closing, with financial results and guidance updated accordingly. These deals collectively illustrate how infectious disease prevention is being repositioned, not as a standalone therapeutic category, but as infrastructure for reducing the long-term burden of some of medicine's most intractable conditions.

How Does Lilly's Oncology Pipeline Reflect the Same Upstream Thinking?

The infectious disease strategy Lilly outlined this month does not exist in isolation.2 At the American Society of Clinical Oncology Annual Meeting the company will present data across a portfolio that increasingly reflects the same logic: intervening earlier, with more targeted tools, to alter long-term disease trajectory. Two presentations have been selected for the meeting's Plenary Session. Primary event-free survival results from the Phase III LIBRETTO-432 study of selpercatinib as adjuvant therapy in fusion-positive non-small cell lung cancer will be featured alongside an investigator-initiated Phase III trial evaluating abemaciclib in advanced dedifferentiated liposarcoma, a rare soft tissue cancer with limited treatment options.

The meeting will also include the first clinical results for an investigational antibody drug conjugate targeting Nectin-4 in advanced urothelial carcinoma, representing an early proof-of-concept readout for a next-generation platform Lilly is actively expanding.2 Updated data from Kelonia Therapeutics' in vivo chimeric antigen receptor T-cell program in relapsed and refractory multiple myeloma will also be presented, ahead of that acquisition's expected close in the second half of 2026.

The breadth of modalities on display, targeted small molecules, antibody drug conjugates, and in vivo cell therapy, underscores how diversified Lilly's technology platform strategy has become across both infectious disease and oncology.2

References

1. Lilly announces three acquisitions to build infectious disease portfolio. Eli Lilly and Company. News release. May 26, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease
2. Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting. Eli Lilly and Company. News release. May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-showcase-oncology-portfolio-across-tumor-types-and